U.S. drugmaker Pfizer beat Wall Street estimates for fourth-quarter profit on Tuesday, helped by cost-cutting efforts and ...

It isn’t entirely clear why the efficacy ... least two years. Pfizer executives, meanwhile, pledged to increase their shot’s market share during a January investor call. Moderna has said ...

The company will compete in a market where GSK and Pfizer already have a presence. Earlier this month, Moderna released data ... to compare the safety and efficacy of its RSV shot with others ...

1 lineage of Omicron but is already being superseded by sister strain KP.3. Still, Pfizer/BioNTech and Moderna say they expect their new vaccines will retain protective efficacy as the two strains ...

According to Pfizer and BioNTech, this is the first time that an mRNA-based flu vaccine has started a phase 3 efficacy trial. Its rival Moderna said earlier this month, however, that it has ...

The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health ...

Besides the impact of a narrowed CDC policy, RSV incumbents GSK and Pfizer apparently ... from an efficacy perspective. The commercialization challenge also showed up for Moderna’s COVID business.

Moderna's mRESVIA must contend with Abrysvo from Pfizer and Arexvy from GSK ... for a norovirus vaccine candidate that could produce efficacy data this year, depending on how rapidly new cases ...

suggests the Moderna vaccine’s advantage in terms of long-term protection. In multiple independent studies, significantly lower antibody levels and more vaccine breakthrough infections have been ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...

During the initial outbreak of Covid-19, China discouraged the use of international vaccines Moderna and Pfizer instead promoted ... had received 97 per cent efficacy in Chinese vaccines.